Breaking News
Get 40% Off 0
🤑 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool. See stock ideas
Close

Fuji Pharma Co Ltd (4554)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1,518.0 -26.0    -1.68%
02:00:29 - Closed. Currency in JPY ( Disclaimer )
  • Volume: 98,800
  • Bid/Ask: 1,518.0 / 1,522.0
  • Day's Range: 1,503.0 - 1,530.0
Type:  Equity
Market:  Japan
ISIN:  JP3816200004 
Fuji Pharma Co Ltd 1,518.0 -26.0 -1.68%

4554 Balance Sheet

 
Featured here, the Balance Sheet for Fuji Pharma Co Ltd, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
Advanced Balance Sheet
Period Ending: 2024
31/03
2023
31/12
2023
30/09
2023
30/06
Total Current Assets - 40400 39114 38297
Cash and Short Term Investments - 2161 2324 3975
Cash - - - -
Cash & Equivalents - 2161 2324 3975
Short Term Investments - - - -
Total Receivables, Net - 16746 16520 14997
Accounts Receivables - Trade, Net - 16737 16304 14585
Total Inventory - 20830 19371 18524
Prepaid Expenses - - - -
Other Current Assets, Total - 663 899 801
Total Assets - 84583 85332 84393
Property/Plant/Equipment, Total - Net - 21179 20547 19820
Property/Plant/Equipment, Total - Gross - - - -
Accumulated Depreciation, Total - - - -
Goodwill, Net - 332 412 492
Intangibles, Net - 9999 10081 9493
Long Term Investments - 6147 14702 16137
Note Receivable - Long Term - 9 216 412
Other Long Term Assets, Total - 5208 1 1
Other Assets, Total - 6065 4225 4481
Total Current Liabilities - 27710 29771 28844
Accounts Payable - 6775 5672 7108
Payable/Accrued - - - -
Accrued Expenses - 264 883 474
Notes Payable/Short Term Debt - 11300 11300 11300
Current Port. of LT Debt/Capital Leases - 3647 5724 5943
Other Current liabilities, Total - 5724 6192 4019
Total Liabilities - 42601 44156 43951
Total Long Term Debt - 12423 11924 12439
Long Term Debt - 7983 8683 9083
Capital Lease Obligations - 4440 3241 3356
Deferred Income Tax - - - 215
Minority Interest - 2 2 2
Other Liabilities, Total - -27916 -31334 -31952
Total Equity - 41982 41176 40442
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total - 3799 3799 3799
Additional Paid-In Capital - 4409 4409 4409
Retained Earnings (Accumulated Deficit) - 31348 29082 27629
Treasury Stock - Common - -554 -567 -567
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total - 2980 4453 5172
Total Liabilities & Shareholders' Equity - 84583 85332 84393
Total Common Shares Outstanding 24.31 24.31 24.3 24.3
Total Preferred Shares Outstanding - - - -
* In Millions of JPY (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

4554 Comments

Write your thoughts about Fuji Pharma Co Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email